Skip to main content

Table 1 Characteristics of patients on methadone treatment for opioid use disorder

From: Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study

Characteristic

Total (N = 240)

Responders (n = 167)

Nonresponders (n = 73)

p value

Age in years; mean (SD)

37.1 (10.4)

37.1 (10.7)

36.9 (9.6)

0.868

Male; n (%)

144 (60.0)

105 (62.9)

39 (53.4)

0.169

Married/common law; n (%)

93 (38.8)

66 (39.5)

27 (37.0)

0.711

Employed; n (%)

72 (30.0)

53 (31.7)

19 (26.0)

0.375

Completed post-secondary education; n (%)

81 (33.8)

52 (31.1)

29 (39.7)

0.196

Ethnicity

 European; n (%)

203 (84.6)

139 (83.2)

64 (87.7)

0.381

 Native North/South American; n (%)

19 (7.9)

14 (8.4)

5 (6.8)

0.686

 Asian; n (%)

2 (0.8)

2 (1.2)

0 (0)

0.348

 Persian; n (%)

1 (0.4)

1 (0.6)

0 (0)

0.508

Age of initial opioid use in years; mean (SD)

23.1 (9.2)

22.3 (8.8)

25.0 (9.8)

0.037

Current cigarette smokers; n (%)

214 (89.2)

145 (86.8)

69 (94.5)

0.210

Number of cigarettes smoked/day; mean (SD)

18.0 (10.1)

18.6 (10.5)

16.6 (9.2)

0.158

Psychiatric comorbidity, self-reported; n (%)

116 (48.3)

81 (48.5)

35 (47.9)

0.937

Family psychiatric history; n (%)

195 (81.3)

133 (79.6)

62 (84.9)

0.334

Alcohol use disorder; n (%)

42 (17.5)

29 (17.4)

13 (17.8)

0.934

Methadone dose (mg); mean (SD)

89.5 (60.8)

97.5 (67.5)

71.2 (35.9)

0.002

Duration of MMT (months); mean (SD)

40.5 (42.6)

44.2 (44.1)

31.8 (37.8)

0.042

Total number of opioid urine screens; mean (SD)

65.7 (23.7)

64.9 (20.7)

67.5 (29.6)

0.278

Opioid use (% positive urine screens); mean (SD)

18.9 (24.1)

5.4 (5.6)

49.8 (21.4)

<0.001

BDNF rs6265 genotype frequencies; n (%)

 G/G

153 (63.8)

110 (65.9)

43 (58.9)

0.302

 A/G

81 (33.8)

52 (31.1)

29 (39.7)

0.196

 A/A

6 (2.5)

5 (3.0)

1 (1.4)

0.458

DRD2 rs1799978 genotype frequencies; n (%)

 A/A

213 (88.8)

150 (89.8)

63 (86.3)

0.427

 A/G

27 (11.3)

17 (10.2)

10 (13.7)

0.427

  1. Frequency for DRD2 rs1799978 G/G genotype is 0 % in this sample; therefore, descriptive statistics are not available
  2. BDNF brain-derived neurotrophic factor, DRD2 dopamine receptor D2, SD standard deviation, MMT methadone maintenance treatment